Overview

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca